Corazza Monica, Virgili Annarosa, Toni Giulia, Borghi Alessandro
a Dipartimento di Scienze Mediche, Sezione di Dermatologia e Malattie Infettive , Università degli Studi di Ferrara , Ferrara , Italy.
J Dermatolog Treat. 2018 May;29(3):305-309. doi: 10.1080/09546634.2017.1360990. Epub 2017 Aug 9.
To assess the effectiveness, tolerability, and convenience of the cream formulation of mometasone furoate 0.1% (MMF) in the treatment of active vulvar lichen sclerosus (VLS) and to compare the cream with the ointment formulation.
The following efficacy parameters were assessed in 27 VLS patients treated with MMF cream for 12 weeks (group A): (i) response rate, (ii) percentage of patients achieving an improvement from baseline of ≥75% in subjective and objective scores, and (iii) mean reduction in subjective and objective scores. These efficacy assessments, as well as those regarding safety and adherence, were compared with the assessments recorded among 37 VLS patients treated with MMF ointment (group B).
59.3% (group A) and 78.4% (group B) of patients were considered responders; 44.4% and 40.7% of patients in group A and 54.1% and 45.9% in group B achieved an improvement of at least 75% in subjective and objective scores, respectively. MMF ointment obtained a significantly higher improvement in symptom scores in comparison with the cream formulation.
MMF in ointment formulation seems to be more effective in treating active VLS in comparison with MMF cream. Both formulations are well tolerated and there is no difference in patient adherence and satisfaction.
评估0.1%糠酸莫米松（MMF）乳膏制剂治疗活动性外阴硬化性苔藓（VLS）的有效性、耐受性和便利性，并将该乳膏与软膏制剂进行比较。
对27例接受MMF乳膏治疗12周的VLS患者（A组）评估以下疗效参数：（i）缓解率，（ii）主观和客观评分较基线改善≥75%的患者百分比，以及（iii）主观和客观评分的平均降低值。将这些疗效评估以及安全性和依从性评估与37例接受MMF软膏治疗的VLS患者（B组）记录的评估结果进行比较。
A组59.3%和B组78.4%的患者被视为有反应者；A组分别有44.4%和40.7%的患者以及B组分别有54.1%和45.9%的患者主观和客观评分改善至少75%。与乳膏制剂相比，MMF软膏在症状评分方面有显著更高的改善。
与MMF乳膏相比，MMF软膏制剂在治疗活动性VLS方面似乎更有效。两种制剂耐受性均良好，患者依从性和满意度无差异。
